Managing gastro-oesophageal reflux disease in primary care

International Journal of Clinical Practice

Volumn 55, Issue 7, 2001, Pages 465-469

  Nathoo, V ^a,b  

^a Five Oaks Family Practice   (United States)

^b Five Oaks Family Practice   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ESOMEPRASOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ALGORITHM; BLEEDING; CLINICAL TRIAL; COMPLICATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DYSPEPSIA; FUNCTIONAL DISEASE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SURGERY; HEART DISEASE; HUMAN; LONG TERM CARE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT DISEASE; REFLUX ESOPHAGITIS; REVIEW; SYMPTOM; WEIGHT REDUCTION;

ALGORITHMS; DRUGS, NON-PRESCRIPTION; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; PRIMARY HEALTH CARE; PROTON PUMPS; RECURRENCE;

EID: 0034815284     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. National Institute for Clinical Excellence. Guidance on the use of proton pump inhibitors in the treatment of dyspepsia. London, 2000.
2. Rush DR, Stelmach WJ, Young TL et al. Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: a clinical experience network (CEN) study. J Fam Pract 1995; 41: 126-136.
3. Carlsson R, Dent J, Bolling-Sternevald E et al. The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998; 33: 1023-1029.
4. Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992; 51(suppI 1): 24-29.
5. Jones RH, Lydeard SE, Hobbs FD et al. Dyspepsia in England and Scotland. Gut 1990; 31: 401-405.
6. Heading RC. Prevalence of upper gastrointestinal symptoms in the general population: a systematic review. Scand J Gastroenterol 1999; 231(suppl): 3-8.
7. Jones R, Lydeard S. Prevalence of symptoms of dyspepsia in the community. BMJ 1989; 298: 30-32.
8. Jones R. Gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1995; 211(suppl): 35-38.
9. Corder AP, Jones RH, Sadler GH et al. Heartburn, oesophagitis and Barren's oesophagus in self-medicating patients in general practice. Br J Clin Pract 1996; 50: 245-248.
10. Nebel OT, Fomes MF, Castell DO. Symptomatic gastrooesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976; 21: 953-956.
11. Bardhan KD, Royston C, Nayyar AK. Reflux rising! A disease in evolution? Gut 2000; 46: TH67.
12. Jones R, Hungin A, Phillips J et al. Gastro-oesophageal reflux disease in primary care in Europe: clinical presentation and endoscopie findings. Eur J Gen Pract 1995; 1: 149-154.
13. Robinson M, Earnest D, Rodriguez-Stanley S et al. Heartburn requiring frequent antacid use may indicate significant illness. Arch Intern Med 1998; 158: 2373-2376.
14. Fennerty MB, Castell D, Fendrick AM el al. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment: suggested disease management guidelines. Arch Inlern Med 1996; 156: 477-484.
15. Penston JG. Pounder RE. A survey of dyspepsia in Great Britain. Aliment Pharmacol Ther 1996: 10: 83-89.
16. Walsh JH. When does heartburn warrant more concern'.' Gastroenterotogy 1999; 117: 293.
17. Jasani K. Piterman L, McCall L. Gastroesophageal reflux and quality of life: patients' knowledge, attitudes and perceptions. Aust Fum Physician 1999:28(suppl 1): S15-S18.
18. Lagergren J, Bergstrom R. Nyren O. No relation between body mass and gastro-oesophageal reflux symptoms in a Swedish population based study. Gut 2000: 47: 26-29.
19. Heading RC. The role of PPIs in the management of GORD. Prescriber 2000; 5 March: 95-103.
20. Dent J, Brun J, Fendrick A et al. An evidence-based appraisal of reflux disease management: the Genval Workshop Report. Gut 1999; 44(suppl 2): S1-S16.
21. Hungin AP. Rubin GP, O'Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999; 49: 451-453.
22. Spechler S. Barren's esophagus: an overrated cancer risk factor. Gaslroenlerology 2000; 119: 587-589.
23. Smout A. Endoscopy negative acid reflux disease. Aliment Pharmacol Ther 1997; Il(suppl2): 81-86.
24. Carlsson R, Frison L, Lundell L et al. Relationship between symptoms, endoscopie findings and treatment outcome in reflux esophagitis. Gastroenterology 1996: 110: A77.
25. Csendes A. Smok G, Cerda G et al. Prevalence of Helicobacter pylori infection in 190 control subjects and in 236 patients with gastroesophageal reflux, erosive esophagitis or Barrett's esophagus. Dis Esophagus 1997; 10: 38-42.
26. Labenz J. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterologv 1997; 112: 1442-1447.
27. Labenz J. Malfertheiner P. Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor? Gut 1997; 41: 277-280.
28. Hession P, Malagelada J-R. The initial management of uninvestigated dyspepsia in younger patients: the value of symptom-guided strategies should be reconsidered. Aliment Pharmacol Ther 2000: 14: 379-388.
29. Sonnenberg A. Delco F, El-Serag HB. Empirical therapy versus diagnostic tests in gastroesophageal reflux disease: a medical decision analysis. Dig Dis Sci 1998: 43: 1001-1008.
30. Talley NJ, Silverstein MD. Agreus L et al. AGA technical review: evaluation of dyspepsia. Gastroenterology 1998; 114: 582-595.
31. De Vault KR, Castell DO, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gaslroenterol 1999;94: 1434-1442.
32. Rang J-Y. Lifestyle measures and reflux. Aliment Pharmacol Ther 2000: 14: 1103.
33. Talley NJ, Venables TH, Green JRB et al. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopynegative GERD: a placebo-controlled on-demand therapy for 6 months. Gastroemewlogy 2000; 118(suppl 2): A658.
34. Talley NJ, Lauristen K, Tunturi-Hihnala H et al. Esomeprazole 20 mg maintains symptom control in endoscopy-negative GERD: a randomized placebo-controlled trial of on-demand therapy for 6 months. Gastroenieroloj-y 2000; 118(suppl 2): A21.
35. Katz PO, Anderson C, Khoury R, Castell DO. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998; 12: 1231-1234.
36. Richter J. Kahrilas P, Hwang C et al. Esomeprazole is superior to omeprazole for the healing of erosive esophagitis (EE) in GERD patients. Gastroenterology 2000; 118(suppl 2): A20.
37. Kahrilas P, Falk G. Whipple J et al. Comparison of esomeprazole: anovel PPI vs omeprazole in GERD patients with erosive esophagitis (EE). Gastroenterology 2000; 118(suppl 2): A193.
38. Kahrilas PJ. Laparoscopic antireflux surgery: silver bullet or the emperor's new clothes? Am J Gastroenterol 1999; 94: 1721-1723.
39. Bate CM. The management of acid-related disorders: the burden of disease and the need for effective treatment. J Med Econ 1998; 1: 51-67.